Filspari sparsentan

Drug Class

Dual endothelin and angiotensin II receptor antagonist

Mechanism

Sparsentan blocks both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, preventing downstream pathway activation linked to proteinuria and kidney damage.

Approved Indication

Treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression to slow kidney function decline; and to reduce proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS).

What This Means For Patients

Filspari is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2024) — Sources

Pivotal Clinical Evidence

• PROTECT — Heerspink et al., Lancet 2023 (NCT03762850) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/filspari
• https://doi.org/10.1016/S0140-6736(23)02302-4